Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development.

Eur J Pharm Biopharm

Late Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.

Published: March 2016

AI Article Synopsis

Article Abstract

Photostability studies are standard stress testing conducted during drug product development of various pharmaceutical compounds, including small molecules and proteins. These studies as recommended by ICH Q1B are carried out using no less than 1.2× 10(6)lux-hours in the visible region and no less than 200Wh/m(2) in UV light. However, normal drug product processing is carried out under fluorescent lamps that emit white light almost exclusively in the >400nm region with a small UV quotient. We term these as ambient or mild light conditions. We tested several IgG1 monoclonal antibodies (mAbs 1-5) under these ambient light conditions and compared them to the ICH light conditions. All the mAbs were significantly degraded under the ICH light but several mAbs (mAbs 3-5) were processed without impacting any product quality attributes under ambient or mild light conditions. Interestingly we observed site-specific Trp oxidation in mAb1, while higher aggregation and color change were observed for mAb2 under mild light conditions. The recommended ICH light conditions have a high UV component and hence may not help to rank order photosensitivity under normal protein DP processing conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2015.12.003DOI Listing

Publication Analysis

Top Keywords

light conditions
24
drug product
12
mild light
12
ich light
12
light
9
ambient light
8
igg1 monoclonal
8
monoclonal antibodies
8
product processing
8
recommended ich
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!